Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kelley Parato"'
Autor:
Abhirami A Ananth, Lee-Hwa Tai, Casey Lansdell, Almohanad A Alkayyal, Katherine E Baxter, Leonard Angka, Jiqing Zhang, Christiano Tanese de Souza, Kyle B Stephenson, Kelley Parato, Jonathan L Bramson, John C Bell, Brian D Lichty, Rebecca C Auer
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159471 (2016)
[This corrects the article DOI: 10.1371/journal.pone.0155947.].
Externí odkaz:
https://doaj.org/article/6726513060824e6e936b2c00406b88c8
Autor:
Abhirami A Ananth, Lee-Hwa Tai, Casey Lansdell, Almohanad A Alkayyal, Katherine E Baxter, Leonard Angka, Jiqing Zhang, Christiano Tanese de Souza, Kyle B Stephenson, Kelley Parato, Jonathan L Bramson, John C Bell, Brian D Lichty, Rebecca C Auer
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155947 (2016)
Anti-tumor CD8+ T cells are a key determinant for overall survival in patients following surgical resection for solid malignancies. Using a mouse model of cancer vaccination (adenovirus expressing melanoma tumor-associated antigen (TAA)-dopachrome ta
Externí odkaz:
https://doaj.org/article/551c7ca1f5e9471199f644eceec99f59
Publikováno v:
Current Opinion in Virology. 13:49-54
Oncolytic immunotherapies (OI) selectively infect, amplify within and destroy cancer cells, thereby representing a novel class of anti-cancer therapy. In addition to this primary mechanism-of-action (MOA), OI based on vaccinia have been shown to sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a119051e54a4874453ab72637e69225e
https://doi.org/10.1016/j.coviro.2015.03.016
https://doi.org/10.1016/j.coviro.2015.03.016
Autor:
Theresa Falls, Kelley Parato, David P. Conrad, Fabrice Le Boeuf, Jean-Simon Diallo, Chantal G Lemay, Harold L. Atkins, John C. Bell, Jovian Tsang, Meaghan Maclean
Publikováno v:
Clinical Cancer Research. 19:3832-3843
Purpose: Acute lymphoblastic leukemia (ALL) remains incurable in most adults. It has been difficult to provide effective immunotherapy to improve outcomes for the majority of patients. Rhabdoviruses induce strong antiviral immune responses. We hypoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d03e46e5c5cb237316d68853646d9c28
https://doi.org/10.1158/1078-0432.ccr-12-3199
https://doi.org/10.1158/1078-0432.ccr-12-3199
Autor:
David F. Stojdl, Jennifer M Paterson, John C. Bell, Fabrice Le Boeuf, Agnieszka Kus, Byram W. Bridle, Rozanne Arulanandam, Brian D. Lichty, Rebecca C. Auer, David P. Conrad, Harold L. Atkins, Julia L Rintoul, Vera A Tang, Jean-Simon Diallo, Kelley Parato, Vanessa Garcia, Kenneth Garson, Lisa Ferreira, Chantal G Lemay, Barbara C. Vanderhyden, Theresa Falls
Publikováno v:
Molecular Therapy. 20(9):1791-1799
Treatment of permissive tumors with the oncolytic virus (OV) VSV-Δ51 leads to a robust antitumor T-cell response, which contributes to efficacy; however, many tumors are not permissive to in vivo treatment with VSV-Δ51. In an attempt to channel the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630dcf6f15609c7a620dfe69de6b3ba8
Autor:
James M. Burke, Kelley Parato, Caroline J. Breitbach, John C. Bell, Ta-Chiang Liu, Tae-Ho Hwang, Yeon-Sook Lee, Anne Moon, David H. Kirn, Naomi De Silva, Joe Stephenson, Manijeh Daneshmand, Antoni Ribas, Jean-Simon Diallo
Publikováno v:
Molecular Therapy. 19(10):1913-1922
JX-594 is a targeted and granulocyte macrophage-colony stimulating factor (GM-CSF)-expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In order to study the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113fa129d58513ddb8f39df8b2529479
Autor:
Byung-Geon Rhee, Mi-Kyung Kim, Theresa Hickman, Caroline J. Breitbach, Tae-Ho Hwang, Yu Kyung Lee, Sung Yong Oh, Julia L Rintoul, Theresa Falls, David H. Kirn, Hyun Young Woo, Anne Moon, Jeong Heo, John C. Bell, Rick Patt, Kelley Parato, Chang Won Kim
Publikováno v:
Molecular Therapy. 19:1170-1179
JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In a phase 1 trial, JX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecd99664ec430247ef9d1f979849cb32
https://doi.org/10.1038/mt.2011.39
https://doi.org/10.1038/mt.2011.39
Autor:
Dominique Vaillant, Kelley Parato, John C. Bell, John Kelly, Ta-Chiang Liu, David H. Kirn, Jiahu Wang, Beichen Sun, Donna L. Senger, Jennifer A. Chan, Peter A. Forsyth, Owen Owen Stechishin, Caroline J. Breitbach, Xueqing Lun, Hongyuan Zhou, Kang Hu
Publikováno v:
Molecular Therapy
The purpose of this study was to investigate the oncolytic potential of the recombinant, granulocyte macrophage colony-stimulating factor (GM-CSF)-expressing vaccinia virus (VV) JX-594 in experimental malignant glioma (MGs) in vitro and in immunocomp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96405cfd7f16c31255147cac15cb11ce
Autor:
Brian D. Lichty, Marianne M. Stanford, Theresa Falls, Christopher W. Brown, John C. Bell, J. Andrea McCart, Jean-Simon Diallo, Rebecca C. Auer, Kelley Parato, David H. Kirn, Steve H. Thorne, Fabrice Le Boeuf, Femina Kanji, Harold L. Atkins
Publikováno v:
Molecular Therapy. 18:888-895
A major barrier to all oncolytic viruses (OVs) in clinical development is cellular innate immunity, which is variably active in a spectrum of human malignancies. To overcome the heterogeneity of tumor response, we combined complementary OVs that atta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a00082ef73982a88774092c4f235b167
https://doi.org/10.1038/mt.2010.44
https://doi.org/10.1038/mt.2010.44
Autor:
Jian Qiao, Jay D. Naik, John C. Bell, Hongxun Wang, K.J. Harrington, Kelley Parato, Timothy Kottke, Richard G. Vile, Candice Willmon, Andrew W. Hudacek, Jill Thompson, Rosa Maria Diaz, Alan Melcher, John D. Chester, Peter Selby
Publikováno v:
Gene Therapy. 15:604-616
Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic virotherapy has recently emerged as a promi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3c04928b6ae93a55e20118c78b6b75
https://doi.org/10.1038/sj.gt.3303098
https://doi.org/10.1038/sj.gt.3303098